Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa

BEDFORD, Texas, July 19, 2021 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, today annou… Read full article

Leave a comment

Your email address will not be published. Required fields are marked *